Related references
Note: Only part of the references are listed.Safety of Human Papillomavirus Vaccines: An Updated Review
Anastasia Phillips et al.
DRUG SAFETY (2018)
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
Marc Arbyn et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25years: event-triggered analysis of a randomized controlled trial
Feng-cai Zhu et al.
CANCER MEDICINE (2017)
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
Kimberley Kavanagh et al.
LANCET INFECTIOUS DISEASES (2017)
Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
Susanne Hartwig et al.
INFECTIOUS AGENTS AND CANCER (2017)
Surveillance of effects of HPV vaccination in Belgium
Marc Arbyn et al.
CANCER EPIDEMIOLOGY (2016)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M. Wheeler et al.
LANCET INFECTIOUS DISEASES (2016)
Is HPV vaccination in pregnancy safe?
Ulla Bonde et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2015)
Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa
Nelly Mugo et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial
Feng-cai Zhu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years Results from 2 randomized controlled trials
Fengcai Zhu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women Open follow-up of a randomized clinical trial up to 4 years post-vaccination
Ryo Konno et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 1826years
Hiroyuki Yoshikawa et al.
CANCER SCIENCE (2013)
Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women
Papa Salif Sow et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types
Davit Bzhalava et al.
VIROLOGY (2013)
Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls
Court Pedersen et al.
JOURNAL OF ADOLESCENT HEALTH (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Human Papillomavirus Vaccines - Immune Responses
Margaret Stanley et al.
VACCINE (2012)
Worldwide burden of cervical cancer in 2008
M. Arbyn et al.
ANNALS OF ONCOLOGY (2011)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
Seung Cheol Kim et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2011)
Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls
Channa E. Schmeink et al.
VACCINE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
Doris M. Rivera Medina et al.
JOURNAL OF ADOLESCENT HEALTH (2010)
Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis-inactivated Poliovirus Vaccine to Girls and Young Women
Jose Garcia-Sicilia et al.
JOURNAL OF ADOLESCENT HEALTH (2010)
Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings
Laia Bruni et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
Young-Jae Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
Neerja Bhatla et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2010)
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine
Ali Rowhani-Rahbar et al.
VACCINE (2009)
Why CIN3 and CIN2 should be distinguished on histological reports
A. Herbert et al.
CYTOPATHOLOGY (2008)
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects
S. Kang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Efficacy and other milestones for human papillomavirus vaccine introduction
SR Pagliusi et al.
VACCINE (2004)
A controlled trial of a human papillomavirus type 16 vaccine
LA Koutsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
